Aging Clinical and Experimental Research

, Volume 5, Issue 2, pp 123–133 | Cite as

Cognitive decline in the elderly: A double- blind, placebo- controlled multicenter study on efficacy of phosphatidylserine administration

  • Teresa Cenacchi
  • T. Bertoldin
  • C. Farina
  • M. G. Fiori
  • G. Crepaldi
  • C. F. Azzini
  • R. Girardello
  • B. Bagozzi
  • R. Garuti
  • P. Vivaldi
  • G. Belloni
  • A. Bordin
  • M. Durando
  • M. Lo Storto
  • L. Bertoni
  • A. Battistoni
  • C. Cacace
  • P. Arduini
  • A. Bonini
  • M. P. Caramia
  • G. Vaglieri
  • A. Brusomini
  • G. Donà
  • A. March
  • N. Campi
  • P. Cannas
  • F. Casson
  • G. Cavallarin
  • M. Delia
  • G. Cristianini
  • O. Louvier
  • F. Mello
  • R. Fameli
  • N. Urbani de Gheltoff
  • O. De Candia
  • G. Nante
  • C. Cattoni
  • P. L. Forte
  • M. Loreggian
  • A. Targa
  • G. Mansoldo
  • G. Noro
  • A. Meggio
  • F. Pedrazzi
  • F. Bonmartini
  • C. Ruggiano
  • M. Peruzza
  • G. Olivari
  • E. Recaldin
  • C. Bellunato
  • G. Rigo
  • M. Marin
  • L. Marinangeli
  • A. Saracino
  • O. Miceli
  • G. Lovo
  • R. Scarpa
  • L. Battistello
  • E. Tomat
  • B. Bernava
  • P. Olivo
  • G. Verga
  • G. Merli
  • A. M. Zerman
  • R. Crivellaro
  • A. Vozza
  • G. R. Ziliotto
  • V. Favaretto
  • L. Allegro
Original Articles

Abstract

This double- blind study assesses the therapeutic efficacy and the safety of oral treatment with phosphatidylserine (BC- PS) vs placebo (300 mg/day for 6 months) in a group of geriatric patients with cognitive impairment. A total of 494 elderly patients (age between 65 and 93 years), with moderate to severe cognitive decline, according to the Mini Mental State Examination and Global DeteriorationScale, were recruited in 23 Geriatric or General Medicine Units in Northeastern Italy. Sixty- nine patients dropped out within the 6- month trial period. Patients were examined just before starting therapy, and 3 and 6 months thereafter. The efficacy of treatment compared to placebo was measured on the basis of changes occurring in behavior and cognitive performance using the Plutchik Geriatric Rating Scale and the Buschke Selective Reminding Test. Statistically significant improvements in the phosphatidylserine- treated group compared to placebo were observed both in terms of behavioral and cognitive parameters. In addition, clinical evaluation and laboratory tests demonstrated that BC- PS was well tolerated. These results are clinically important since the patients were representative of the geriatric population commonly met in clinical practice. (Aging Clin. Exp. Res. 5: 123- 133, 1993).

Keywords

Cognitive decline elderly phosphatidylserine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Greene J.G., Smith R., Gardiner M., Timbury G.C.: Measuring behavioural disturbance of elderly demented patients in the community and its effects on relatives: a factor analytic study. Age Ageing 11: 121–126, 1982.PubMedCrossRefGoogle Scholar
  2. 2.
    Folstein M.F., Anthony J.C., Parhad I., Duffy B., Gruenberg E.M.: The meaning of cognitive impairment in the elderly. J. Am. Geriatr. Soc. 33: 228–235, 1985.PubMedGoogle Scholar
  3. 3.
    Katzman R.: Alzheimer’s disease. N. Engl. J. Med. 314: 964–973, 1986.PubMedCrossRefGoogle Scholar
  4. 4.
    Svennerholm L., Bostrom K., Heiander C.G., Jungbjer B.: Membrane lipids in the aging human brain. J. Neurochem. 56: 2051–2059, 1991.PubMedCrossRefGoogle Scholar
  5. 5.
    Schroeder F.: Role of membrane lipid asymmetry in aging. Neurobiol. Aging 5: 323–333, 1984.PubMedCrossRefGoogle Scholar
  6. 6.
    Rapoport S.I., London E.D.: Brain metabolism during aging of the rat and dog. Implications for brain function in man during aging and dementia. In: Terry R.D., Bolis C.G., Toffano G. (Eds.), Neural Aging and its implications in human neurological pathology. Raven Press, New York, 1982, pp. 79–88.Google Scholar
  7. 7.
    Hirata F., Axelrod J.: Phospholipid methylation and biological signal transmission. Science 209: 1082–1090, 1980.PubMedCrossRefGoogle Scholar
  8. 8.
    DeKosky S.T., Scheff S.W.: Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity. Ann. Neurol. 27: 457–464, 1990.PubMedCrossRefGoogle Scholar
  9. 9.
    Feinstein A.R.: An additional basic science for clinical medicine: II. The limitations of randomized trials. Ann. Intern. Med. 99: 544–550, 1983.CrossRefGoogle Scholar
  10. 10.
    Toffano G., Bruni A.: Pharmacological properties of phospholipid liposomes. Pharmacol. Res. Commun. 12: 829–845, 1980.PubMedCrossRefGoogle Scholar
  11. 11.
    Calderini G., Bellini F., Bonetti A.C., Galbiati E., Guidolin D., Milan F., Nunzi M.G., Rubini R., Zanotti A., Toffano G.: Pharmacological properties of phosphatidylserine in the ageing brain. Clin. Trials J. 24: 9–17, 1987.Google Scholar
  12. 12.
    Toffano G., Leon A., Mazzari S., Savoini G., Teolato S., Orlando P.: Modification of noradrenergic hypothalamic system in rat injected with phosphatidylserine liposomes. Life Sci. 23: 1093–1102, 1987.CrossRefGoogle Scholar
  13. 13.
    Mazzari S., Battistella A.: Phosphatidylserine effects on dopamine release from striatum synaptosomes. In: Di Benedetta C., Balazs R., Gombos G., Porcellati G. (Eds.), Multidisciplinary approach to brain development. North-Holland/Elsevier, Amsterdam, 1980, pp. 569–570.Google Scholar
  14. 14.
    Vannucchi M.G., Pepeu G.: Effect of phosphatidylserine on acetylcholine release and content in cortical slices from aging rats. Neurobiol. Aging 8: 403–407, 1987.PubMedCrossRefGoogle Scholar
  15. 15.
    Casamenti F., Scali C., Pepeu G.: Phosphatidylserine reverses the age-dependent decrease in cortical acetylcholine release: a microdialysis study. Eur. J. Pharmacol. 194: 11–16, 1991.PubMedCrossRefGoogle Scholar
  16. 16.
    Nunzi M.G., Milan F., Guidolin D., Toffano G.: Dendritic spine loss in hippocampus of aged rats. Effect of brain phosphatidylserine administration. Neurobiol. Aging 8: 501–551, 1987.CrossRefGoogle Scholar
  17. 17.
    Guidolin D., Milan F., Polato P., Nunzi M.G., Toffano G.: Phosphatidylserine treatment prevents age-induced structural alterations in the rat septo-hippocampal system. In: Bazan N.G., Horrocks L.A., Toffano G. (Eds.), Phospholipid in the nervous system: biochemical and molecular pathology. Liviana Press, Padova, 1989, pp. 183–193.Google Scholar
  18. 18.
    Corwin J., Dean R.L. III, Bartus R.T., Rotrosen J., Watkins D.L.: Behavioral effects of phosphatidylserine in the aged Fischer 344 rat: amelioration of passive avoidance deficits without changes in psychomotor task performance. Neurobiol. Aging 6: 11–15, 1985.PubMedCrossRefGoogle Scholar
  19. 19.
    Drago F., Canonico P.L., Scapagnini U.: Behavioral effects of phosphatidylserine in aged rats. Neurobiol. Aging 2: 209–213, 1981.PubMedCrossRefGoogle Scholar
  20. 20.
    Zanotti A., Valzelli L., Toffano G.: Chronic phosphatidylserine treatment improves spatial memory and passive avoidance in aged rats. Psychopharmacology 99: 316–321, 1989.PubMedCrossRefGoogle Scholar
  21. 21.
    Amaducci L., Crook T.H., Lippi A.: Use of phosphatidylserine in Alzheimer’s Disease. Ann. N.Y. Acad. Sci. 640: 245–249, 1991.PubMedGoogle Scholar
  22. 22.
    Monteleone P., Beinat L., Tanzillo C., Maj M., Kemali D.: Effects of phosphatidylserine on the neuroendocrine response to physical stress in humans. Neuroendocrinology 52: 243–248, 1990.PubMedCrossRefGoogle Scholar
  23. 23.
    Monteleone P., Maj M., Beinat L., Natale M., Kemali D.: Blunting by chronic phosphatidylserine of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men. Eur. J. Clin. Pharmacol. 41: 385–388, 1992.Google Scholar
  24. 24.
    Rosadini G., Sannita W.G., Nobili F., Cenacchi T.: Phosphatidylserine: quantitative EEG effects in healthy volunteers. Neuropsychobiology 24: 42–48, 1991.CrossRefGoogle Scholar
  25. 25.
    Klinkhammer P., Szelies B., Heiss W.D.: Effect of phosphatidylserine on cerebral glucose metabolism in Alzheimer’s disease. Dementia 1: 197–201, 1990.Google Scholar
  26. 26.
    Palmieri G., Palmieri R., Inzoli M.R., Lomabardi G., Sottini C., Tavolato B., Giometto B.: Double-blind controlled trial of phosphatidylserine in patients with senile mental deterioration. Clin. Trials J. 24: 73–83, 1987.Google Scholar
  27. 27.
    Villardita C., Grioli S., Salmeri G., Nicoletti F., Pennisi G.: Multicentre clinical trial of brain phosphatidylserine in elderly patients with intellectual deterioration. Clin. Trials J. 24: 84–93, 1987.Google Scholar
  28. 28.
    Maggioni M., Picotti G.B., Bondiolotti G.P., Panerai A., Cenacchi T., Nobile P., Brambilla F.: Effects of phosphatidylserine therapy in geriatric patients with depressive disorders. Acta Psychiatr. Scand. 81: 265–270, 1990.PubMedCrossRefGoogle Scholar
  29. 29.
    Crook T.H., Tinklenberg J., Yesavage J., Petrie W., Nunzi M.G., Massari C.D.: Effects of phosphatidylserine in age-associated memory impairment. Neurology 41: 644–649, 1991.PubMedCrossRefGoogle Scholar
  30. 30.
    Delwaide P.J., Gyselynck-Mambourg A.M., Hurlet A., Ylieff M.: Double-blind randomized controlled study of phosphatidylserine in senile demented patients. Acta Neurol. Scand. 73: 136–140, 1986.PubMedCrossRefGoogle Scholar
  31. 31.
    Amaducci L. and the SMID Group: Phosphatidylserine in the treatment of Alzheimer’s disease: results of a multicenter study. Psychopharmacol. Bull. 24: 130–134, 1988.PubMedGoogle Scholar
  32. 32.
    Folstein M.F., Folstein S.E., McHugh P.R.: “Mini Mental State”. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12: 189–198, 1975.PubMedCrossRefGoogle Scholar
  33. 33.
    Reisberg B.: The brief cognitive rating scale and Global Deterioration Scale. In: Crook T., Ferris S., Bartus R. (Eds.), Assessment in Geriatric Psychopharmacology. Mark Powley Associates, New Canaan, Connecticut, 1983, pp. 19–28.Google Scholar
  34. 34.
    Reisberg B., Ferris S.H., Crook T.: Guidelines for drug trials in the treatment of age-associated cognitive decline and Alzheimer’s disease. Drug Inf. J. 19: 405–420, 1985.Google Scholar
  35. 35.
    Wells C.E.: Pseudodementia. Am. J. Psychiatry 136: 895–900, 1979.PubMedGoogle Scholar
  36. 36.
    Blessed G., Tomlinson B.E., Roth M.: The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br. J. Psychiatry 114: 797–811, 1968.PubMedCrossRefGoogle Scholar
  37. 37.
    Hamilton M.: A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23: 56–62, 1960.PubMedCrossRefGoogle Scholar
  38. 38.
    Hamilton M.: Rating depressive patients. J. Clin. Psychiatry 41: 21–24, 1980.PubMedGoogle Scholar
  39. 39.
    Plutchik R., Conte H., Lieberman M., Bakur M., Grossman J., Lehrman N.: Reliability and validity of a scale for assessing the functioning of geriatric patients. J. Am. Geriatr. Soc. 18: 491–500, 1970.PubMedGoogle Scholar
  40. 40.
    Buschke H., Fuld P.A.: Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology 24: 1019–1025, 1974.PubMedCrossRefGoogle Scholar
  41. 41.
    Smith J.M., Bright B., McCloskey J.: Factor analytic composition of the Geriatric Rating Scale (GRS). J. Gerontol. 32: 58–62, 1977.PubMedCrossRefGoogle Scholar
  42. 42.
    Muramoto O.: Selective reminding in normal and demented aged people: auditory verbal versus visual spatial task. Cortex 20: 461–478, 1984.PubMedCrossRefGoogle Scholar
  43. 43.
    Bartolini V., Tagliavini C., Zampolli A.: Lessico di Frequenza della Lingua Italiana Contemporanea. Garzanti, Milano, 1972.Google Scholar
  44. 44.
    Bertoldin T., Farina C., Crepaldi G.: Memory function, cognitive status and aging: a study employing MMSE and Selective Reminding Technique. The Third Congress of the International Psychogeriatric Association, Chicago, Illinois, U.S.A., 1987, pp. 97–98, (Abstract).Google Scholar
  45. 45.
    Hachinski V., Iliff L., Du Boulay G., Phil M., Zilhka E, McAllister L., Marshall J.: Cerebral blood flow in dementia. Arch. Neurol 32: 632–637, 1975.PubMedCrossRefGoogle Scholar
  46. 46.
    Fleiss J.L.: Analysis of data from Multicentric Trials. Controlled Clin. Trials 7: 267–275, 1986.PubMedCrossRefGoogle Scholar
  47. 47.
    Larson E.B., Reifler B.V., Sumi S.M., Canfield C.G., Chinn N.M.: Diagnostic evaluation of 200 elderly outpatients with suspected dementia. J. Gerontol. 40: 536–543, 1985.PubMedCrossRefGoogle Scholar
  48. 48.
    Parkin A.J., Walter B.M.: Aging, short-term memory, and frontal dysfunction. Psychobiology 19: 175–179, 1991.Google Scholar

Copyright information

© Editrice Kurtis s.r.l. 1993

Authors and Affiliations

  • Teresa Cenacchi
    • 1
  • T. Bertoldin
    • 2
  • C. Farina
    • 3
  • M. G. Fiori
    • 1
  • G. Crepaldi
    • 2
  • C. F. Azzini
    • 4
  • R. Girardello
    • 4
  • B. Bagozzi
    • 5
  • R. Garuti
    • 5
  • P. Vivaldi
    • 5
  • G. Belloni
    • 6
  • A. Bordin
    • 6
  • M. Durando
    • 6
  • M. Lo Storto
    • 6
  • L. Bertoni
    • 7
  • A. Battistoni
    • 7
  • C. Cacace
    • 7
  • P. Arduini
    • 7
  • A. Bonini
    • 8
  • M. P. Caramia
    • 8
  • G. Vaglieri
    • 8
  • A. Brusomini
    • 9
  • G. Donà
    • 9
  • A. March
    • 9
  • N. Campi
    • 10
  • P. Cannas
    • 10
  • F. Casson
    • 11
  • G. Cavallarin
    • 11
  • M. Delia
    • 11
  • G. Cristianini
    • 12
  • O. Louvier
    • 12
  • F. Mello
    • 13
  • R. Fameli
    • 13
  • N. Urbani de Gheltoff
    • 13
  • O. De Candia
    • 14
  • G. Nante
    • 14
  • C. Cattoni
    • 14
  • P. L. Forte
    • 15
  • M. Loreggian
    • 15
  • A. Targa
    • 15
  • G. Mansoldo
    • 16
  • G. Noro
    • 16
  • A. Meggio
    • 16
  • F. Pedrazzi
    • 17
  • F. Bonmartini
    • 17
  • C. Ruggiano
    • 17
  • M. Peruzza
    • 18
  • G. Olivari
    • 18
  • E. Recaldin
    • 19
  • C. Bellunato
    • 19
  • G. Rigo
    • 20
  • M. Marin
    • 20
  • L. Marinangeli
    • 20
  • A. Saracino
    • 21
  • O. Miceli
    • 21
  • G. Lovo
    • 21
  • R. Scarpa
    • 22
  • L. Battistello
    • 22
  • E. Tomat
    • 23
  • B. Bernava
    • 23
  • P. Olivo
    • 23
  • G. Verga
    • 24
  • G. Merli
    • 24
  • A. M. Zerman
    • 25
  • R. Crivellaro
    • 25
  • A. Vozza
    • 25
  • G. R. Ziliotto
    • 26
  • V. Favaretto
    • 26
  • L. Allegro
    • 26
  1. 1.Fidia Research LaboratoriesAbano Terme (Padova)Italy
  2. 2.Institute of Internal MedicineUniversity of PadovaPadova
  3. 3.Third Division of GeriatricsGeriatric HospitalPadovaItaly
  4. 4.Geriatric Dept.HospitalMalo, VI
  5. 5.Geriatric Dept.HospitalTrento
  6. 6.2nd Dept.Geriatric HospitalPadova
  7. 7.2nd Medical Dept.HospitalVerona
  8. 8.3rd Medical Dept.HospitalTrieste
  9. 9.Geriatric Dept.HospitalBolzano
  10. 10.Medical Dept.HospitalTregnago
  11. 11.Medical Dept.HospitalChioggia
  12. 12.Medical Dept.HospitalGorizia
  13. 13.1st Dept.Geriatric HospitalVenezia
  14. 14.3rd Dept.Geriatric HospitalPadova
  15. 15.Geriatric Dept.HospitalRovigo
  16. 16.Geriatric Dept.HospitalRovereto
  17. 17.1st Medical Dept.HospitalVerona
  18. 18.2nd Dept.Geriatric HospitalVenezia
  19. 19.Geriatric Dept.HospitalNegrar
  20. 20.Geriatric Dept.HospitalMarostica, VI
  21. 21.Geriatric Dept.HospitalPiove di Sacco
  22. 22.Geriatric Dept.HospitalChioggia
  23. 23.3rd Medical Dept.Hospital
  24. 24.Geriatric Dept.HospitalLegnago
  25. 25.3rd Medical Dept.HospitalVerona
  26. 26.1st Dept.Geriatric HospitalPadova

Personalised recommendations